The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 05 2023
05 05 2023
Historique:
received:
19
10
2022
accepted:
24
04
2023
medline:
8
5
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
epublish
Résumé
Renal cancer cells constitute a paradigm of tumor cells with a glycolytic reprogramming which drives metabolic alterations favouring cell survival and transformation. We studied the expression and activity of pyruvate dehydrogenase kinases (PDK1-4), key enzymes of the energy metabolism, in renal cancer cells. We analysed the expression, subcellular distribution and clinicopathological correlations of PDK1-4 by immunohistochemistry of tumor tissue microarray samples from a cohort of 96 clear cell renal cell carcinoma (ccRCC) patients. Gene expression analysis was performed on whole tumor tissue sections of a subset of ccRCC samples. PDK2 and PDK3 protein expression in tumor cells correlated with lower patient overall survival, whereas PDK1 protein expression correlated with higher patient survival. Gene expression analysis revealed molecular association of PDK2 and PDK3 expression with PI3K signalling pathway, as well as with T cell infiltration and exhausted CD8 T cells. Inhibition of PDK by dichloroacetate in human renal cancer cell lines resulted in lower cell viability, which was accompanied by an increase in pAKT. Together, our findings suggest a differential role for PDK enzymes in ccRCC progression, and highlight PDK as actionable metabolic proteins in relation with PI3K signalling and exhausted CD8 T cells in ccRCC.
Identifiants
pubmed: 37147361
doi: 10.1038/s41598-023-34087-x
pii: 10.1038/s41598-023-34087-x
pmc: PMC10162970
doi:
Substances chimiques
Pyruvate Dehydrogenase Acetyl-Transferring Kinase
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Oxidoreductases
EC 1.-
Pyruvates
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7339Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Hay, N. Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy?. Nat. Rev. Cancer 16, 635–649. https://doi.org/10.1038/nrc.2016.77 (2016).
doi: 10.1038/nrc.2016.77
pubmed: 27634447
pmcid: 5516800
Soga, T. Cancer metabolism: Key players in metabolic reprogramming. Cancer Sci. 104, 275–281. https://doi.org/10.1111/cas.12085 (2013).
doi: 10.1111/cas.12085
pubmed: 23279446
pmcid: 7657261
Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141–162. https://doi.org/10.1038/s41573-021-00339-6 (2022).
doi: 10.1038/s41573-021-00339-6
pubmed: 34862480
Lu, Z. & Hunter, T. Metabolic kinases moonlighting as protein kinases. Trends Biochem. Sci. 43, 301–310. https://doi.org/10.1016/j.tibs.2018.01.006 (2018).
doi: 10.1016/j.tibs.2018.01.006
pubmed: 29463470
pmcid: 5879014
Ngo, D. C., Ververis, K., Tortorella, S. M. & Karagiannis, T. C. Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol. Biol. Rep. 42, 819–823. https://doi.org/10.1007/s11033-015-3857-y (2015).
doi: 10.1007/s11033-015-3857-y
pubmed: 25672512
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K. & Pal, S. Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochim. Biophys. Acta Rev. Cancer 1876, 188559. https://doi.org/10.1016/j.bbcan.2021.188559 (2021).
doi: 10.1016/j.bbcan.2021.188559
pubmed: 33965513
pmcid: 8349779
Guo, H. et al. The PI3K/AKT pathway and renal cell carcinoma. J. Genet. Genomics 42, 343–353. https://doi.org/10.1016/j.jgg.2015.03.003 (2015).
doi: 10.1016/j.jgg.2015.03.003
pubmed: 26233890
pmcid: 4624215
Maher, E. R. Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management. World J. Urol. 36, 1891–1898. https://doi.org/10.1007/s00345-018-2288-5 (2018).
doi: 10.1007/s00345-018-2288-5
pubmed: 29680948
pmcid: 6280834
Haas, N. B. & Nathanson, K. L. Hereditary kidney cancer syndromes. Adv. Chronic Kidney Dis. 21, 81–90. https://doi.org/10.1053/j.ackd.2013.10.001 (2014).
doi: 10.1053/j.ackd.2013.10.001
pubmed: 24359990
Linehan, W. M. et al. The metabolic basis of kidney cancer. Cancer Discov. 9, 1006–1021. https://doi.org/10.1158/2159-8290.CD-18-1354 (2019).
doi: 10.1158/2159-8290.CD-18-1354
pubmed: 31088840
Massari, F. et al. Metabolic alterations in renal cell carcinoma. Cancer Treat. Rev. 41, 767–776. https://doi.org/10.1016/j.ctrv.2015.07.002 (2015).
doi: 10.1016/j.ctrv.2015.07.002
pubmed: 26169313
Delahunt, B. & Srigley, J. R. The evolving classification of renal cell neoplasia. Semin. Diagn. Pathol. 32, 90–102. https://doi.org/10.1053/j.semdp.2015.02.002 (2015).
doi: 10.1053/j.semdp.2015.02.002
pubmed: 25753529
Henegan, J. C. Jr. & Gomez, C. R. Heritable cancer syndromes related to the hypoxia pathway. Front. Oncol. 6, 68. https://doi.org/10.3389/fonc.2016.00068 (2016).
doi: 10.3389/fonc.2016.00068
pubmed: 27047799
pmcid: 4801850
Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 32, 1968–1976. https://doi.org/10.1200/JCO.2012.45.2003 (2014).
doi: 10.1200/JCO.2012.45.2003
pubmed: 24821879
pmcid: 4050206
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49. https://doi.org/10.1038/nature12222 (2013).
doi: 10.1038/nature12222
Gerlinger, M. et al. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur. Urol. 67, 729–737. https://doi.org/10.1016/j.eururo.2014.04.014 (2015).
doi: 10.1016/j.eururo.2014.04.014
pubmed: 24836153
Sankin, A. et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 3, 1485–1492. https://doi.org/10.1002/cam4.293 (2014).
doi: 10.1002/cam4.293
pubmed: 25124064
pmcid: 4298374
Lopez, J. I. & Angulo, J. C. Pathological bases and clinical impact of intratumor heterogeneity in clear cell renal cell carcinoma. Curr. Urol. Rep. 19, 3. https://doi.org/10.1007/s11934-018-0754-7 (2018).
doi: 10.1007/s11934-018-0754-7
pubmed: 29374850
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623. https://doi.org/10.1016/j.cell.2018.02.020 (2018).
doi: 10.1016/j.cell.2018.02.020
pubmed: 29656891
pmcid: 5927631
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594. https://doi.org/10.1016/j.cell.2018.03.057 (2018).
doi: 10.1016/j.cell.2018.03.057
pubmed: 29656895
pmcid: 5938365
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595–610. https://doi.org/10.1016/j.cell.2018.03.043 (2018).
doi: 10.1016/j.cell.2018.03.043
pubmed: 29656894
pmcid: 5938372
Okegawa, T. et al. Intratumor heterogeneity in primary kidney cancer revealed by metabolic profiling of multiple spatially separated samples within tumors. EBioMedicine 19, 31–38. https://doi.org/10.1016/j.ebiom.2017.04.009 (2017).
doi: 10.1016/j.ebiom.2017.04.009
pubmed: 28408240
pmcid: 5440602
Sradhanjali, S. & Reddy, M. M. Inhibition of pyruvate dehydrogenase kinase as a therapeutic strategy against cancer. Curr. Top. Med. Chem. 18, 444–453. https://doi.org/10.2174/1568026618666180523105756 (2018).
doi: 10.2174/1568026618666180523105756
pubmed: 29788890
Stacpoole, P. W. Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J. Natl. Cancer Inst. 109, 11. https://doi.org/10.1093/jnci/djx071 (2017).
doi: 10.1093/jnci/djx071
Saunier, E., Benelli, C. & Bortoli, S. The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int. J. Cancer 138, 809–817. https://doi.org/10.1002/ijc.29564 (2016).
doi: 10.1002/ijc.29564
pubmed: 25868605
Patel, M. S., Nemeria, N. S., Furey, W. & Jordan, F. The pyruvate dehydrogenase complexes: Structure-based function and regulation. J. Biol. Chem. 289, 16615–16623. https://doi.org/10.1074/jbc.R114.563148 (2014).
doi: 10.1074/jbc.R114.563148
pubmed: 24798336
pmcid: 4059105
Kinnaird, A. et al. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur. Urol. 69, 734–744. https://doi.org/10.1016/j.eururo.2015.09.014 (2016).
doi: 10.1016/j.eururo.2015.09.014
pubmed: 26433571
Atas, E., Oberhuber, M. & Kenner, L. The implications of PDK1–4 on tumor energy metabolism, aggressiveness and therapy resistance. Front. Oncol. 10, 583217. https://doi.org/10.3389/fonc.2020.583217 (2020).
doi: 10.3389/fonc.2020.583217
pubmed: 33384955
pmcid: 7771695
Wang, X., Shen, X., Yan, Y. & Li, H. Pyruvate dehydrogenase kinases (PDKs): An overview toward clinical applications. Biosci. Rep. 41, 402. https://doi.org/10.1042/BSR20204402 (2021).
doi: 10.1042/BSR20204402
Tumkur Sitaram, R., Landstrom, M., Roos, G. & Ljungberg, B. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. J. Clin. Pathol. 74, 216–222. https://doi.org/10.1136/jclinpath-2020-206693 (2021).
doi: 10.1136/jclinpath-2020-206693
pubmed: 32467322
Atkins, M. B. & Tannir, N. M. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat. Rev. 70, 127–137. https://doi.org/10.1016/j.ctrv.2018.07.009 (2018).
doi: 10.1016/j.ctrv.2018.07.009
pubmed: 30173085
Angulo, J. C. & Shapiro, O. The changing therapeutic landscape of metastatic renal cancer. Cancers 11, 1227. https://doi.org/10.3390/cancers11091227 (2019).
doi: 10.3390/cancers11091227
pubmed: 31443471
pmcid: 6770566
Huang, J. J. & Hsieh, J. J. The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age. Semin. Nephrol. 40, 28–41. https://doi.org/10.1016/j.semnephrol.2019.12.004 (2020).
doi: 10.1016/j.semnephrol.2019.12.004
pubmed: 32130964
pmcid: 8858035
Pulido, R. PTEN: A yin-yang master regulator protein in health and disease. Methods 77–78, 3–10. https://doi.org/10.1016/j.ymeth.2015.02.009 (2015).
doi: 10.1016/j.ymeth.2015.02.009
pubmed: 25843297
Yang, J. et al. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol. Cancer 18, 26. https://doi.org/10.1186/s12943-019-0954-x (2019).
doi: 10.1186/s12943-019-0954-x
pubmed: 30782187
pmcid: 6379961
Kankotia, S. & Stacpoole, P. W. Dichloroacetate and cancer: New home for an orphan drug?. Biochim. Biophys. Acta 1846, 617–629. https://doi.org/10.1016/j.bbcan.2014.08.005 (2014).
doi: 10.1016/j.bbcan.2014.08.005
pubmed: 25157892
Weiss, R. H. Metabolomics and metabolic reprogramming in kidney cancer. Semin. Nephrol. 38, 175–182. https://doi.org/10.1016/j.semnephrol.2018.01.006 (2018).
doi: 10.1016/j.semnephrol.2018.01.006
pubmed: 29602399
pmcid: 6009840
Rathmell, W. K., Rathmell, J. C. & Linehan, W. M. Metabolic pathways in kidney cancer: Current therapies and future directions. J. Clin. Oncol. 1, 792309. https://doi.org/10.1200/JCO.2018.79.2309 (2018).
doi: 10.1200/JCO.2018.79.2309
Baumunk, D. et al. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC). World J. Urol. 31, 1191–1196. https://doi.org/10.1007/s00345-012-0874-5 (2013).
doi: 10.1007/s00345-012-0874-5
pubmed: 22544372
Lim, H. Y. et al. Metabolic signatures of renal cell carcinoma. Biochem. Biophys. Res. Commun. 460, 938–943. https://doi.org/10.1016/j.bbrc.2015.03.130 (2015).
doi: 10.1016/j.bbrc.2015.03.130
pubmed: 25839656
Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185. https://doi.org/10.1016/j.cmet.2006.02.002 (2006).
doi: 10.1016/j.cmet.2006.02.002
pubmed: 16517405
Ilic, B. B. et al. VHL dependent expression of REDD1 and PDK3 proteins in clear-cell renal cell carcinoma. J. Med. Biochem. 37, 31–38. https://doi.org/10.1515/jomb-2017-0030 (2018).
doi: 10.1515/jomb-2017-0030
pubmed: 30581339
pmcid: 6294108
Nunes-Xavier, C. E. et al. Heterogeneous expression and subcellular localization of pyruvate dehydrogenase complex in prostate cancer. Front. Oncol. 12, 873516. https://doi.org/10.3389/fonc.2022.873516 (2022).
doi: 10.3389/fonc.2022.873516
pubmed: 35692804
pmcid: 9174590
Kafkia, E. et al. Operation of a TCA cycle subnetwork in the mammalian nucleus. Sci. Adv. 8, 5206. https://doi.org/10.1126/sciadv.abq5206 (2022).
doi: 10.1126/sciadv.abq5206
Li, W. et al. Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation. Nat. Commun. 13, 7414. https://doi.org/10.1038/s41467-022-35199-0 (2022).
doi: 10.1038/s41467-022-35199-0
pubmed: 36460681
pmcid: 9718843
Nagaraj, R. et al. Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation. Cell 168, 210–223. https://doi.org/10.1016/j.cell.2016.12.026 (2017).
doi: 10.1016/j.cell.2016.12.026
pubmed: 28086092
pmcid: 5321559
Sutendra, G. et al. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene 32, 1638–1650. https://doi.org/10.1038/onc.2012.198 (2013).
doi: 10.1038/onc.2012.198
pubmed: 22614004
Bowker-Kinley, M. M., Davis, W. I., Wu, P., Harris, R. A. & Popov, K. M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem. J. 329(Pt 1), 191–196. https://doi.org/10.1042/bj3290191 (1998).
doi: 10.1042/bj3290191
pubmed: 9405293
pmcid: 1219031
Skorja Milic, N. et al. Suppression of Pyruvate Dehydrogenase Kinase by dichloroacetate in cancer and skeletal muscle cells is isoform specific and partially independent of HIF-1alpha. Int. J. Mol. Sci. 22, 8610. https://doi.org/10.3390/ijms22168610 (2021).
doi: 10.3390/ijms22168610
pubmed: 34445316
pmcid: 8395311
Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648. https://doi.org/10.1016/j.ccell.2021.02.013 (2021).
doi: 10.1016/j.ccell.2021.02.013
pubmed: 33711273
pmcid: 8138872
Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight https://doi.org/10.1172/jci.insight.93411 (2017).
doi: 10.1172/jci.insight.93411
pubmed: 28614802
pmcid: 5470888
Wang, Y. et al. Crosstalk between metabolism and immune activity reveals four subtypes with therapeutic implications in clear cell renal cell carcinoma. Front. Immunol. 13, 861328. https://doi.org/10.3389/fimmu.2022.861328 (2022).
doi: 10.3389/fimmu.2022.861328
pubmed: 35479084
pmcid: 9035905
Feng, Q. et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat. Commun. 13, 4981. https://doi.org/10.1038/s41467-022-32521-8 (2022).
doi: 10.1038/s41467-022-32521-8
pubmed: 36068198
pmcid: 9448806
Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655–663. https://doi.org/10.1097/00000478-198210000-00007 (1982).
doi: 10.1097/00000478-198210000-00007
pubmed: 7180965
Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17, 1471–1474. https://doi.org/10.1245/s10434-010-0985-4 (2010).
doi: 10.1245/s10434-010-0985-4
pubmed: 20180029
Lopez, J. I. et al. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Hum. Pathol. 54, 100–105. https://doi.org/10.1016/j.humpath.2016.03.009 (2016).
doi: 10.1016/j.humpath.2016.03.009
pubmed: 27063470
Tang, Z. et al. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102. https://doi.org/10.1093/nar/gkx247 (2017).
doi: 10.1093/nar/gkx247
pubmed: 28407145
pmcid: 5570223